Samfara完成对丹麦受管制物质原料药制造商 Chr. Olesen Synthesis的收购-动脉网

Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs

PR Newswire 等信源发布 2026-10-02 14:00



可切换为仅中文







The acquisition is Samfara's first investment and is backed by a syndicate of European and North American institutional investors and family offices

此次收购是Samfara的首笔投资，由一群欧洲和北美的机构投资者及家族办公室组成的银团提供支持。

LONDON

伦敦

，

Oct. 2, 2026

2026年10月2日

/PRNewswire/ -- Samfara, a European life sciences investment firm, today announced that it has completed the acquisition of Chr. Olesen Synthesis from Chr. Olesen and funds managed by Signet Healthcare Partners. Chief Executive Thomas Moestrup is investing alongside Samfara. Financial terms of the transaction were not disclosed..

/美通社/ -- 欧洲生命科学投资公司Samfara今日宣布，已完成从Chr. Olesen及由Signet Healthcare Partners管理的基金手中收购Chr. Olesen Synthesis的交易。首席执行官Thomas Moestrup将与Samfara共同投资。本次交易的财务条款未予披露。

Based near Copenhagen, Chr. Olesen Synthesis develops and manufactures active pharmaceutical ingredients (APIs) and advanced intermediates, specialising in controlled substances, in particular those used to treat opioid use disorder (buprenorphine) and ADHD (lisdexamfetamine). Its cGMP-certified plant has been in commercial production since 2015 and supplies pharmaceutical companies across Europe, North America and the Middle East.

Chr. Olesen Synthesis 总部位于哥本哈根附近，致力于开发和生产活性药物成分（APIs）及高级中间体，专长于受控物质，特别是用于治疗阿片类药物使用障碍（丁丙诺啡）和注意缺陷多动障碍（ADHD，赖右苯丙胺）的药物。其符合现行药品生产质量管理规范（cGMP）认证的工厂自2015年起投入商业化生产，向欧洲、北美和中东地区的制药公司供应产品。

The business combines technical expertise and a high level of flexibility in serving pharmaceutical customers across its markets..

该企业将专业技术与高度灵活性相结合，为各市场中的制药客户提供服务。

With Samfara's backing, Chr. Olesen Synthesis will continue to develop its capabilities, build on its existing customers and products and expand into new markets. Jean-François Hilaire, former CEO of Unither and former EVP at Recipharm, who advised Samfara on the acquisition, will join the board of Chr.

在Samfara的支持下，Chr. Olesen Synthesis将继续发展其能力，依托现有客户和产品基础，并拓展新市场。曾担任Unither首席执行官及Recipharm执行副总裁的Jean-François Hilaire在此次收购中为Samfara提供咨询建议，他将加入Chr.的董事会。

Olesen Synthesis as Chair..

奥勒森合成公司担任主席

Helena Malchione and James Cocker, Partners of Samfara, said:

Samfara 的合伙人 Helena Malchione 和 James Cocker 表示：

'Chr. Olesen Synthesis illustrates our strategy of finding winning companies in complex niches and backing them with capital and strategic support. It holds a strong position and an excellent reputation in a demanding part of the pharmaceutical market, and we look forward to working with Thomas and the team as they grow with existing customers and expand into new markets, both organically and through acquisitions.'.

“Chr. Olesen Synthesis 案例彰显了我们通过在复杂细分领域发掘优胜企业，并以资本和战略支持为其赋能的投资策略。该公司在要求严苛的制药市场领域中占据强势地位并享有卓越声誉。我们期待与 Thomas 及其团队携手合作，助力其在服务现有客户的同时，通过内生增长和并购方式拓展新市场。”

Thomas Moestrup, Chief Executive of Chr. Olesen Synthesis, said:

Chr. Olesen Synthesis 首席执行官 Thomas Moestrup 表示：

'This is an exciting next step for Chr. Olesen Synthesis. With Samfara as our new owner, we have a partner who shares our ambitions and will support the continued development of the business. We look forward to building on our strong customer relationships, expanding the business and developing the opportunities ahead of us.'.

“这对 Chr. Olesen Synthesis 来说是令人振奋的下一步。随着 Samfara 成为我们的新所有者，我们拥有了一位与我们志同道合、并将支持业务持续发展的合作伙伴。我们期待在稳固的客户关系基础上进一步发展，扩大业务规模，并开拓前方的机遇。”

Mads C. Olesen, Chief Executive and owner of Chr. Olesen, said:

Chr. Olesen 的首席执行官兼所有者 Mads C. Olesen 表示：

'In 2011, Chr. Olesen acquired Chr. Olesen Synthesis and, together with Signet Healthcare, has built it into a significant player in controlled-substance APIs. The time is right for new owners to take the business forward, and we are confident that we have entrusted the company to the right new owner.

2011年，Chr. Olesen收购了Chr. Olesen Synthesis，并与Signet Healthcare携手，将其发展成为受管制物质原料药领域的重要参与者。如今正是新所有者推动公司向前发展的合适时机，我们坚信已将公司托付给合适的新所有者。

We extend our best wishes to Samfara and the management team of the company.'.

我们向Samfara及公司管理团队致以最美好的祝愿。

ADVISERS

顾问

Samfara was advised by Addleshaw Goddard (legal, UK), Connaught (capital formation), infotransactions (financial and tax due diligence), Lockton (W&I insurance), Nivaro Law (legal, Denmark) and RSM (tax structuring).

Samfara 获得了以下机构的顾问服务：Addleshaw Goddard（英国法律）、Connaught（资本募集）、infotransactions（财务与税务尽职调查）、Lockton（保证与赔偿保险）、Nivaro Law（丹麦法律）以及 RSM（税务架构）。

Chr. Olesen and Signet Healthcare Partners were advised by LEK (commercial), Moalem Weitemeyer (legal), Nielsen Nørager (legal), PwC (financial and tax), Sheppard, Mullin, Richter & Hampton (legal), and Stifel (M&A).

Chr. Olesen 和 Signet Healthcare Partners 获得了以下机构的顾问服务：LEK（商业咨询）、Moalem Weitemeyer（法律）、Nielsen Nørager（法律）、普华永道（财务与税务）、Sheppard, Mullin, Richter & Hampton（法律）以及 Stifel（并购）。

ABOUT SAMFARA

关于 SAMFARA

Samfara is a London-based private equity firm focused on majority buyouts of European life sciences companies in the lower mid-market. The firm makes thesis-led investments in complex, international businesses whose performance can be accelerated and transformed through active ownership. Samfara aims to deliver attractive returns for investors while supporting European life sciences companies, the jobs they create and the patients they benefit..

Samfara 是一家总部位于伦敦的私募股权公司，专注于对欧洲中低端市场的生命科学企业进行多数股权收购。该公司以投资理念为导向，投资于复杂的国际化企业，通过积极的所有权管理加速并转型其业务表现。Samfara 旨在为投资者提供可观回报，同时支持欧洲生命科学企业、其所创造的就业岗位以及其所惠及的患者群体。

www.samfara.com

Samfara LLP is an appointed representative of Suntera Advisers (UK) Limited, which is authorised and regulated by the Financial Conduct Authority.

Samfara LLP 是 Suntera Advisers (UK) Limited 的指定代表，Suntera Advisers (UK) Limited 由英国金融行为监管局授权并受其监管。

ABOUT CHR. OLESEN SYNTHESIS

关于 CHR. OLESEN SYNTHESIS

Chr. Olesen Synthesis is a Danish developer and manufacturer of APIs and advanced intermediates, specialising in controlled substances. From its cGMP-certified plant in Hvidovre, near Copenhagen, it supplies pharmaceutical companies across Europe, North America and the Middle East and offers contract development and manufacturing services for new APIs..

Chr. Olesen Synthesis 是一家丹麦原料药和高级中间体开发商及制造商，专注于受控物质。该公司位于哥本哈根附近赫维多雷的 cGMP 认证工厂，向欧洲、北美和中东地区的制药公司供应产品，并提供新原料药的合同开发与制造服务。

www.cosynthesis.dk

ABOUT CHR. OLESEN

关于 CHR. OLESEN

Chr. Olesen, founded in 1885, is a family-owned global distribution company specializing in nutraceutical ingredients for the feed, food, pharma, and technical industries.

Chr. Olesen 成立于1885年，是一家家族拥有的全球分销公司，专注于为饲料、食品、制药和技术行业提供营养保健原料。

www.chr-olesen.dk

ABOUT SIGNET HEALTHCARE PARTNERS

关于Signet Healthcare Partners

Signet Healthcare Partners is a healthcare growth equity firm that invests in commercial-stage pharmaceutical (pharma services and therapeutics) and medical technology companies. Founded in 1998 and based in New York, Signet has invested in more than 60 companies, supporting entrepreneurs with capital, strategic guidance, and deep industry networks..

Signet Healthcare Partners 是一家专注于医疗保健领域的成长型股权投资公司，主要投资于处于商业化阶段的制药（包括制药服务和治疗产品）及医疗技术企业。Signet 成立于 1998 年，总部位于纽约，已投资超过 60 家企业，通过提供资金、战略指导以及深厚的行业网络资源，助力创业者发展。

www.signethealthcarepartners.com

CONTACTS

联系人

Samfara

萨姆法拉

Helena Malchione, Partner

海伦娜·马尔基奥内，合伙人

[email protected]

James Cocker, Partner

詹姆斯·科克尔，合伙人

[email protected]

Chr. Olesen Synthesis